Screener
AnaptysBio, Inc. ANAB Royalty Management Company — Interest Income Other
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by AnaptysBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeOther.
The source filing: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219515
| Line item | Biopharma | Royalty Management | Total |
|---|---|---|---|
| Total G&A | 18,856 | 7,346 | 26,202 |
| Total operating expenses | 52,811 | 7,382 | 60,193 |
| (Loss) income from operations | (52,811) | 18,174 | (34,637) |
| Interest income | 2,328 | 325 | 2,653 |
| Non-cash interest expense | — | (20,859) | (20,859) |
| Other expense, net | (1) | — | (1) |
| Total other income (expense), net | 2,327 | (20,534) | (18,207) |
| Loss before income taxes | (50,484) | (2,360) | (52,844) |
Item 1. Consolidated Financial Statements
FAQ
- What is AnaptysBio, Inc.'s royalty management company — interest income other?
- AnaptysBio, Inc. (ANAB) reported royalty management company — interest income other of $325K in Q1 2026.
- How has AnaptysBio, Inc.'s royalty management company — interest income other changed year-over-year?
- AnaptysBio, Inc.'s royalty management company — interest income other increased by 0.9% year-over-year, from $322K to $325K.
- What does royalty management company — interest income other mean?
- This metric captures interest income earned on cash balances or other financial instruments held specifically by the royalty management segment. It reflects the secondary financial returns generated from the segment's liquidity management activities.
Ask your AI about AnaptysBio, Inc.'s royalty management company — interest income other.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude